Ocrelizumab alters the circulating metabolome in people with relapsing–remitting multiple sclerosis
In this longitudinal observational study, using a global untargeted metabolomics approach, we showed significant alteration in circulating metabolome in RRMS patients undergoing ocrelizumab treatment. In particular, we observed a significant reduction in metabolites involved in the lysophospholipid pathway, which was associated with patients' improvement.
Authors
- Fatemeh Siavoshi (ORCID: https://orcid.org/0000-0002-8562-9523)
- Bardia Nourbakhsh (ORCID: https://orcid.org/0000-0002-6617-2003)
- Dimitrios C. Ladakis (ORCID: https://orcid.org/0000-0002-5764-2114)
- Pavan Bhargava (ORCID: https://orcid.org/0000-0002-7947-9418)
- A. Müller (ORCID: https://orcid.org/0000-0001-8180-4331)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2024-08-26
- DOI
- https://doi.org/10.1002/acn3.52167
- Citations
- 5
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.12
Funders
- National Multiple Sclerosis Society
- Multiple Sclerosis Society
- Genentech